ALBPS Biophytis SA

EPA · FR · Healthcare · Biotechnology · biophytis.com

0.0453EUR-4.23%Mkt Cap: 23.51M $P/E: —3d ago

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company'…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap23.51M USD

Enterprise Value8.19M USD

Revenue (TTM)—

Gross Profit0 USD

Net Income (TTM)-8.73M USD

Revenue/Share—

Last Price0.0453 EUR

Fiscal Year EndDec 2024

MR QuarterJun 2025

Employees19

CountryFR

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-0.02

PEG—

EV/EBITDA-0.96

EV/Revenue—

P/S—

P/B-0.14

EPS (TTM)-0.34

EPS (Forward)-2.15

52W Range

0.004223% of range0.1830

52W High0.1830 EUR

52W Low0.0042 EUR

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE—

ROA-66.56%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-9.39M USD

CapEx (TTM)—

FCF Margin—

FCF Yield-7.56%

Net Debt7.08M USD

Net Debt/EBITDA-0.83

Balance Sheet

Debt/Equity-0.68

Current Ratio0.35

Quick Ratio0.33

Book Value/Sh-0.33 EUR

Cash/Share0.05 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Splits

Last Split1:400

Split DateMay 3, 2024

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.350.13M

Float23.36M

Insiders0.53%

Institutions0.54%

Technical

SMA 500.0562 (-19.4%)

SMA 2000.0388 (+16.6%)

Beta1.65

S&P 52W Chg14.58%

Avg Vol (30d)32.73M

Avg Vol (10d)14.00M

Technical Indicators

RSI (14)43.6

MACD-0.0032

MACD Signal-0.0024

MACD Hist.-0.0008

BB Upper0.0704 EUR

BB Middle0.0531 EUR

BB Lower0.0358 EUR

BB Width65.21%

ATR (14)0.0089 EUR

Vol Ratio (20d)0.33x